ENGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends October 31Also trades as ENGNW

enGene Therapeutics Inc.

Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 8, 2026

$1.58−0.09 (-5.39%)

Close on Oct 19, 2026

Market cap: $110.18M
P/E (TTM): 0.7
Dividend yield: 0.00%

Debt

Borrowings on the balance sheet, Jul 31, 2026

Total debt

$25.16M

Long-term debt

Net debt

-$15.87M

After $41.03M of cash

Implied interest rate

15.84%

FY2025 interest ÷ average debt

Interest coverage

-41.1×

FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, USD

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in enGene Therapeutics's annual report. Trading prices and yields need FINRA TRACE data.